UTMB Researchers Pioneer Single-Dose Vaccine Advancements Against Andes Hantavirus Strain

In a groundbreaking development published in the esteemed journal The Lancet, researchers at The University of Texas Medical Branch (UTMB) have announced the creation of novel mRNA vaccines that provide complete protection against the lethal Andes hantavirus after just one dose in animal models. This significant advancement holds promise for rapidly responding to outbreaks of this deadly virus, which poses an escalating threat to global public health.

The Andes virus is a member of the hantavirus family, notorious for causing severe respiratory illness and high mortality rates. Unlike other hantaviruses that primarily transmit through exposure to infected rodent excreta, the Andes virus exhibits a rare capacity for direct human-to-human transmission via respiratory droplets and close physical contact. This feature drastically increases its epidemic potential, as witnessed in a recent outbreak aboard the Dutch cruise ship MV Hondius, where 13 individuals contracted the virus, and three succumbed to the disease.

The unique human-to-human transmission dynamic presented a formidable challenge in containing the infection, especially considering the virus’s incubation period during which infected individuals remain asymptomatic but contagious. Such stealthy spread necessitates swift interventional measures to prevent larger outbreaks. Recognizing this urgency, UTMB scientists, under the leadership of Dr. Alexander Bukreyev, have leveraged cutting-edge mRNA vaccine technology to address the need for fast-acting prophylactics.

Initial versions of these vaccines, co-developed by Dr. Ivan V. Kuzmin, had already demonstrated robust protection in animal studies employing a two-dose regimen. However, the protracted timeframe required between doses rendered this approach suboptimal for combating rapid international transmission events. To enhance practicality during outbreaks, the team embarked on evaluating the efficacy of single-dose protocols in appropriate preclinical models.

The outcomes surpassed expectations. Experimental results revealed that a single administration of the mRNA vaccines conferred 100% efficacy in preventing disease manifestation in an animal model that closely mimics human infection by Andes virus. Remarkably, this protective effect persisted even when the vaccine dose was substantially reduced to a fraction of the original quantity, underscoring the vaccines’ potent immunogenicity and the precision of their design.

Dr. Michelle Meyer, the study’s lead author, detailed that animals receiving the single-shot vaccines remained clinically healthy post-exposure, exhibiting no signs of illness or weight loss throughout the observation period. Tissue analyses performed a month after viral challenge revealed complete clearance of the virus, attesting to the vaccines’ capacity to induce a rapid and durable immunological defense.

Employing synthetic messenger RNA technology, these vaccines encode viral antigens that prompt host cells to generate targeted immune responses, including neutralizing antibodies and cellular immunity, without exposure to live virus components. This method not only accelerates vaccine design and production but also enhances safety profiles by eliminating the risks associated with traditional attenuated or inactivated virus vaccines.

The practical implications of such rapid-onset immunity are profound. Given the Andes virus’s relatively slow progression to severe disease, these vaccines could be deployed post-exposure to high-risk contacts during outbreaks, acting as an emergency intervention to arrest viral replication before clinical symptoms emerge. This strategy represents a paradigm shift in hantavirus outbreak management, potentially halting chains of transmission early and preventing widespread morbidity and mortality.

Moreover, the vaccines’ ability to evoke protective responses within 14 days aligns with critical windows for outbreak containment, where time is of the essence to thwart the virus’s spread. The scalability of mRNA vaccine platforms further enables expedited manufacturing, ensuring timely availability during emergent situations.

The recent MV Hondius incident, which involved passengers from 23 countries, highlighted the complexities of tracking and controlling hantavirus dissemination across international borders. The silent transmission phase, coupled with global mobility, underscores the necessity for globally deployable vaccines that furnish rapid and reliable immunity.

In addition to Drs. Bukreyev, Kuzmin, and Meyer, researchers Emmett Dews and Matthew Hyde of the Galveston National Laboratory contributed vital expertise supporting this pioneering work. Their collective efforts push the boundaries of viral pathogenesis understanding and immunoprophylaxis, advancing public health preparedness against an unconventional and dangerous pathogen.

Looking ahead, UTMB is collaborating with the National Institutes of Health to transition these vaccine candidates into human clinical trials. These trials will evaluate safety, immunogenicity, and protective efficacy in diverse populations, paving the way for a novel class of vaccines tailored to emergent hantavirus threats.

This research heralds a new era in combating deadly zoonotic viruses with human-to-human transmission capabilities. It exemplifies the synergistic power of mRNA technology and targeted virological research to deliver timely countermeasures that can save lives and mitigate the global burden of infectious diseases.